Jiantao Hu

发表

Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).

Shaomeng Wang, Chao-yie Yang, James Delproposto, 2019, Journal of medicinal chemistry.

Multi-dimensional analyses identify genes of high priority for pancreatic cancer research

Z. Nwosu, Shaomeng Wang, Jiantao Hu, 2021, bioRxiv.

Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.

Liu Liu, Shaomeng Wang, J. Stuckey, 2018, Journal of medicinal chemistry.

Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer

Shaomeng Wang, D. Hayes, Jiantao Hu, 2020, Breast Cancer Research and Treatment.

Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression

Liu Liu, Shaomeng Wang, D. McEachern, 2017, Journal of medicinal chemistry.

Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer.

M. Ellis, Shunqiang Li, Liu Liu, 2017, Cancer research.

Precise Conformational Control Yielding Highly Potent and Exceptionally Selective BRD4 Degraders with Strong Antitumor Activity.

Shaomeng Wang, J. Stuckey, D. McEachern, 2023, Journal of medicinal chemistry.

Toxicities of amyloid-beta and tau protein are reciprocally enhanced in the Drosophila model

Jiantao Hu, Bing Zhou, Yunpeng Huang, 2022, Neural regeneration research.

Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance

A. Chinnaiyan, Jiantao Hu, A. Parolia, 2024, Cell.